Resolve Therapeutics and the Institut Pasteur de Montevideo in Uruguay will collaborate to identify the central upstream triggers that drive inflammation in autoimmune disease.
Damaged, modified self-RNA and endogenous retroviral RNA molecules circulating in the blood are the most proximal triggers of a self-perpetuating inflammatory cascade present in diseases such as lupus and Sjögren’s. Because these molecules are inherently fragile, they are not captured using conventional sequencing methods, resulting in the loss of critical disease-related information. REJOIN-seq is an innovative new technology developed at the Pasteur that restores and repairs partially degraded cfRNA, enabling the sequencing of molecules that have heretofore been lost with conventional sequencing.
“Embedding Pasteur’s next generation RNA-seq technology within Resolve’s clinical programs provides a unique opportunity to significantly advance our understanding of cfRNA in autoimmune diseases,” said James Posada, chief executive officer of Resolve Therapeutics.
“Pasteur’s Dr. Tosar has published some of the most careful, exacting science in the field of cfRNA, we are thrilled to work with his team.”
“We are confident that combining our next generation REJOIN-seq technology with Resolve’s clinical programs will unlock information regarding the upstream events that trigger the inflammatory cascade in autoimmunity,” said Juan Tosar, chief of functional genomics at the Pasteur.